Low-intensity focused ultrasound induces reversal of tumor-induced T cell tolerance and prevents immune escape

Journal of Immunology

Volumn 196, Issue 4, 2016, Pages 1964-1976

  Bandyopadhyay, Sanmay ^a   Quinn, Thomas J ^a   Scandiuzzi, Lisa ^a   Basu, Indranil ^a   Partanen, Ari ^b   Tomé, Wolfgang A ^a   Macian, Fernando ^a,b   Guha, Chandan ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b PHILIPS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASM METASTASIS; PATHOLOGY; PROCEDURES; RADIOTHERAPY; REAL TIME POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR ESCAPE; ULTRASOUND THERAPY;

ANIMALS; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM METASTASIS; RADIOTHERAPY; REAL-TIME POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; T-LYMPHOCYTES; TUMOR ESCAPE; ULTRASONIC THERAPY;

EID: 84958581122     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500541     Document Type: Article

References (65)

1. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296.
2. Dougan, M., and G. Dranoff. 2009. Immune therapy for cancer. Annu. Rev. Immunol. 27: 83-117.
3. Uyttenhove, C., L. Pilotte, I. Théate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, and B. J. Van den Eynde. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9: 1269-1274.
4. Thomas, D. A., and J. Massagué. 2005. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369-380.
5. Gerlini, G., A. Tun-Kyi, C. Dudli, G. Burg, N. Pimpinelli, and F. O. Nestle. 2004. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am. J. Pathol. 165: 1853-1863.
6. Turk, M. J., J. A. Guevara-Patinõ, G. A. Rizzuto, M. E. Engelhorn, S. Sakaguchi, and A. N. Houghton. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200: 771-782.
7. Huang, B., P. Y. Pan, Q. Li, A. I. Sato, D. E. Levy, J. Bromberg, C. M. Divino, and S. H. Chen. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66: 1123-1131.
8. Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117: 1155-1166.
9. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
10. van Elsas, A., A. A. Hurwitz, and J. P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190: 355-366.
11. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377.
12. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 8: 793-800.
13. Rubinstein, N., M. Alvarez, N. W. Zwirner, M. A. Toscano, J. M. Ilarregui, A. Bravo, J. Mordoh, L. Fainboim, O. L. Podhajcer, and G. A. Rabinovich. 2004. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5: 241-251.
14. Troy, A. J., K. L. Summers, P. J. Davidson, C. H. Atkinson, and D. N. Hart. 1998. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4: 585-593.
15. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
16. Willimsky, G., and T. Blankenstein. 2005. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437: 141-146.
17. Overwijk, W. W., M. R. Theoret, S. E. Finkelstein, D. R. Surman, L. A. de Jong, F. A. Vyth-Dreese, T. A. Dellemijn, P. A. Antony, P. J. Spiess, D. C. Palmer, et al. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198: 569-580.
18. Cuenca, A., F. Cheng, H. Wang, J. Brayer, P. Horna, L. Gu, H. Bien, I. M. Borrello, H. I. Levitsky, and E. M. Sotomayor. 2003. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 63: 9007-9015.
19. Zheng, Y., Y. Zha, G. Driessens, F. Locke, and T. F. Gajewski. 2012. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J. Exp. Med. 209: 2157-2163.
20. Sotomayor, E. M., I. Borrello, F. M. Rattis, A. G. Cuenca, J. Abrams, K. Staveley-O'Carroll, and H. I. Levitsky. 2001. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98: 1070-1077.
21. Abe, B. T., D. S. Shin, E. Mocholi, and F. Macian. 2012. NFAT1 supports tumorinduced anergy of CD4(+) T cells. Cancer Res. 72: 4642-4651.
22. Jang, H. J., J.-Y. Lee, D.-H. Lee,W.-H. Kim, and J. H. Hwang. 2010. Current and Future Clinical Applications of High-Intensity Focused Ultrasound (HIFU) for Pancreatic Cancer. Gut Liver 4(Suppl. 1): S57-S61.
23. Kennedy, J. E. 2005. High-intensity focused ultrasound in the treatment of solid tumours. Nat. Rev. Cancer 5: 321-327.
24. Blana, A., B. Walter, S. Rogenhofer, and W. F. Wieland. 2004. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 63: 297-300.
25. Illing, R. O., J. E. Kennedy, F. Wu, G. R. ter Haar, A. S. Protheroe, P. J. Friend, F. V. Gleeson, D. W. Cranston, R. R. Phillips, and M. R. Middleton. 2005. The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population. Br. J. Cancer 93: 890-895.
26. Wu, F., L. Zhou, and W. R. Chen. 2007. Host antitumour immune responses to HIFU ablation. Int. J. Hyperthermia 23: 165-171.
27. Hu, Z., X. Y. Yang, Y. Liu, M. A. Morse, H. K. Lyerly, T. M. Clay, and P. Zhong. 2005. Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem. Biophys. Res. Commun. 335: 124-131.
28. Hu, Z., X. Y. Yang, Y. Liu, G. N. Sankin, E. C. Pua, M. A. Morse, H. K. Lyerly, T. M. Clay, and P. Zhong. 2007. Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J. Transl. Med. 5: 34.
29. Liu, H. L., H. Y. Hsieh, L. A. Lu, C. W. Kang, M. F. Wu, and C. Y. Lin. 2012. Low-pressure pulsed focused ultrasound with microbubbles promotes an anticancer immunological response. J. Transl. Med. 10: 221.
30. Basu, S., and P. K. Srivastava. 1999. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor-and peptide-specific immunity. J. Exp. Med. 189: 797-802.
31. Castelli, C., A. M. Ciupitu, F. Rini, L. Rivoltini, A. Mazzocchi, R. Kiessling, and G. Parmiani. 2001. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res. 61: 222-227.
32. Haug, M., L. Dannecker, C. P. Schepp, W. W. Kwok, D. Wernet, J. H. Buckner, H. Kalbacher, G. E. Dannecker, and U. Holzer. 2005. The heat shock protein Hsp70 enhances antigen-specific proliferation of human CD4+ memory T cells. Eur. J. Immunol. 35: 3163-3172.
33. Pawaria, S., and R. J. Binder. 2011. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat. Commun. 2: 521.
34. Wells, A. D., M. C. Walsh, J. A. Bluestone, and L. A. Turka. 2001. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J. Clin. Invest. 108: 895-903.
35. Gajewski, T. F., S. R. Woo, Y. Zha, R. Spaapen, Y. Zheng, L. Corrales, and S. Spranger. 2013. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25: 268-276.
36. Driessens, G., J. Kline, and T. F. Gajewski. 2009. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol. Rev. 229: 126-144.
37. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736.
38. Munn, D. H., and A. L. Mellor. 2007. Indoleamine 2,3-dioxygenase and tumorinduced tolerance. J. Clin. Invest. 117: 1147-1154.
39. Green, D. R., T. Ferguson, L. Zitvogel, and G. Kroemer. 2009. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9: 353-363.
40. Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5: 677-685.
41. Valdor, R., and F. Macian. 2013. Induction and stability of the anergic phenotype in T cells. Semin. Immunol. 25: 313-320.
42. Macián, F., F. García-Cózar, S. H. Im, H. F. Horton, M. C. Byrne, and A. Rao. 2002. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109: 719-731.
43. Safford, M., S. Collins, M. A. Lutz, A. Allen, C. T. Huang, J. Kowalski, A. Blackford, M. R. Horton, C. Drake, R. H. Schwartz, and J. D. Powell. 2005. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat. Immunol. 6: 472-480.
44. Soto-Nieves, N., I. Puga, B. T. Abe, S. Bandyopadhyay, I. Baine, A. Rao, and F. Macian. 2009. Transcriptional complexes formed by NFAT dimers regulate the induction of T cell tolerance. J. Exp. Med. 206: 867-876.
45. Enk, A. H., H. Jonuleit, J. Saloga, and J. Knop. 1997. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer 73: 309-316.
46. Marangoni, F., T. T. Murooka, T. Manzo, E. Y. Kim, E. Carrizosa, N. M. Elpek, and T. R. Mempel. 2013. The transcription factor NFAT exhibits signal memory during serial T cell interactions with antigen-presenting cells. Immunity 38: 237-249.
47. Srivastava, P. 2002. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20: 395-425.
48. Udono, H., and P. K. Srivastava. 1993. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178: 1391-1396.
49. Udono, H., and P. K. Srivastava. 1994. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 152: 5398-5403.
50. Ullrich, S. J., E. A. Robinson, L. W. Law, M. Willingham, and E. Appella. 1986. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc. Natl. Acad. Sci. USA 83: 3121-3125.
51. Somersan, S., M. Larsson, J. F. Fonteneau, S. Basu, P. Srivastava, and N. Bhardwaj. 2001. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J. Immunol. 167: 4844-4852.
52. Liu, B., A. M. DeFilippo, and Z. Li. 2002. Overcoming immune tolerance to cancer by heat shock protein vaccines. Mol. Cancer Ther. 1: 1147-1151.
53. Chen, X., Q. Tao, H. Yu, L. Zhang, and X. Cao. 2002. Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity. Immunol. Lett. 84: 81-87.
54. Vega, V. L., M. Rodríguez-Silva, T. Frey, M. Gehrmann, J. C. Diaz, C. Steinem, G. Multhoff, N. Arispe, and A. De Maio. 2008. Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. J. Immunol. 180: 4299-4307.
55. Basu, S., R. J. Binder, R. Suto, K. M. Anderson, and P. K. Srivastava. 2000. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 12: 1539-1546.
56. Obeid, M., T. Panaretakis, A. Tesniere, N. Joza, R. Tufi, L. Apetoh, F. Ghiringhelli, L. Zitvogel, and G. Kroemer. 2007. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res. 67: 7941-7944.
57. Boussiotis, V. A., D. L. Barber, T. Nakarai, G. J. Freeman, J. G. Gribben, G. M. Bernstein, A. D. D'Andrea, J. Ritz, and L. M. Nadler. 1994. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 266: 1039-1042.
58. Duré, M., and F. Macian. 2009. IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes. Mol. Immunol. 46: 999-1006.
59. Gao, B., Q. Kong, K. Kemp, Y. S. Zhao, and D. Fang. 2012. Analysis of sirtuin 1 expression reveals a molecular explanation of IL-2-mediated reversal of T-cell tolerance. Proc. Natl. Acad. Sci. USA 109: 899-904.
60. Gramaglia, I., A. D. Weinberg, M. Lemon, and M. Croft. 1998. Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161: 6510-6517.
61. Lathrop, S. K., C. A. Huddleston, P. A. Dullforce, M. J. Montfort, A. D. Weinberg, and D. C. Parker. 2004. A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. J. Immunol. 172: 6735-6743.
62. Murata, S., B. H. Ladle, P. S. Kim, E. R. Lutz, M. E. Wolpoe, S. E. Ivie, H. M. Smith, T. D. Armstrong, L. A. Emens, E. M. Jaffee, and R. T. Reilly. 2006. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J. Immunol. 176: 974-983.
63. Tsushima, F., S. Yao, T. Shin, A. Flies, S. Flies, H. Xu, K. Tamada, D. M. Pardoll, and L. Chen. 2007. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 110: 180-185.
64. Wilcox, R. A., K. Tamada, D. B. Flies, G. Zhu, A. I. Chapoval, B. R. Blazar, W. M. Kast, and L. Chen. 2004. Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood 103: 177-184.
65. Zhang, L., X. Chen, X. Liu, D. E. Kline, R. M. Teague, T. F. Gajewski, and J. Kline. 2013. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J. Clin. Invest. 123: 1999-2010.